Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Neladenoson Bialanate in Renal Impairment
NCT04320771Phase 1Terminated
- Sponsor
- Bayer
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of neladenoson bialanate in chronic heart failure (CHF) (4 arms), sponsored by Bayer. Primary endpoints: Maximum observed drug concentration in plasma, Area under the concentration-time curve and 5 more. Started Nov 2017; status: terminated.
02
Drugs
neladenoson bialanate
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT04320771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320771.